Comparative Pharmacology
Head-to-head clinical analysis: DUREZOL versus FLUOR OP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DUREZOL versus FLUOR OP.
DUREZOL vs FLUOR-OP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid receptor agonist; reduces inflammation by inhibiting phospholipase A2, decreasing prostaglandin and leukotriene synthesis, and suppressing immune cell migration and cytokine release.
Fluorometholone is a corticosteroid that inhibits phospholipase A2, reducing arachidonic acid release and subsequent prostaglandin and leukotriene synthesis, thereby suppressing inflammatory responses.
1 drop of 0.1% ophthalmic solution in the affected eye(s) four times daily for up to 14 days.
2 drops of 0.1% solution into the affected eye(s) every 15 minutes for 4 doses, then every 30 minutes for 2 doses, then every 1-2 hours for 24-48 hours, then tapering over 1-2 weeks; alternatively, 0.5 cm ribbon of 0.05% ointment into the conjunctival sac 4-6 times daily.
None Documented
None Documented
Terminal elimination half-life is 12–18 hours in adults; prolonged to 24–36 hours in hepatic impairment.
Terminal elimination half-life is 3-6 hours in adults with normal renal function; prolonged to 12-24 hours in severe renal impairment (CrCl <30 mL/min), necessitating dose adjustment.
Renal excretion of unchanged drug accounts for 30% of clearance; biliary/fecal elimination accounts for 60%, with the remainder as metabolites.
Renal excretion of unchanged drug accounts for approximately 60-80% of elimination, with the remainder as metabolites (glucuronide conjugates) via urine; fecal elimination is minimal (<5%).
Category C
Category C
Ophthalmic Corticosteroid
Ophthalmic Corticosteroid